Clinical Trial Update: The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating CT1192 for safety, efficacy, and cellular metabolic kinetics in ANCA-associated vasculitis; the study status is not yet recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis

Drugs mentioned

• CT1192

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: ANCA Associated Vasculitis (AAV) | Phase 1 | Status: NOT_YET_RECRUITING